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Radical prostatectomy in patients with preoperative prostate specific antigen
15ng/ml and higher
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Amos Douvdevani3, Inoel Rivera1, Zev Wajsman1
O b j e c t i v e.  To report on the outcome of patients who underwent radical prostatectomy (RP) with preoperative PSA≥15
ng/ml.
M e t h o d s.  Eighty-five consecutive patients with PSA ≥15ng/ml (median 26 ng/ml, range 15-126 ng/ml) underwent RP be-
tween 1989 and 1997. Patients with palpable cancer received 3 months neoadjuvant hormone therapy. Thirty-six patients (42%)
underwent early (3-4 months after RP) adjuvant radiation for pT3 disease and/or positive surgical margins.
R e s u l t s.  The median follow-up was 58 months (range 2 – 104 mos.). The overall relapse rate was 33%. Six patients
(7%) died during follow up, three due to metastatic prostate cancer. Patients with T1c tumors had a significantly lower recur-
rence rate than those with palpable (cT2 and cT3) cancer (p=0.03). Age above 65 was found to be a significant negative pro-
gnostic factor with respect to biochemical recurrence (p=0.01). Adjuvant radiation was associated with significantly lower bio-
chemical recurrence rates compared to patients who were not radiated. (p=0.05).
Overall, the preoperative PSA level was not found to have prognostic significance with respect to the biochemical recurrence
in this group of patients. However, in patients with seminal vesicle invasion (pT3c) patients with biochemical recurrence had
a significantly higher preoperative PSA (p=0.05)
C o n c l u s i o n s.  In selected patients with nonpalpable prostate cancer and with preoperative PSA≥15 ng/ml (median 26
ng/ml) RP is a feasible treatment option. In young patients with prostate cancer, the level of serum PSA should be used selec-
tively as a contraindication for RP. If extra capsular tumor extension is diagnosed in these patients we encourage a multimo-
de treatment approach incorporating adjuvant postoperative radiation.
Radykalna prostatektomia u chorych z wysokim przedoperacyjnym poziomem PSA (>15ng/ml)
C e l.  Ocena wyników leczenia radykalnà prostatektomià (RP) chorych, z przedoperacyjnym wysokim poziomem PSA (15
ng/ml.
M a t e r i a ∏  i m e t o d a.  W okresie 1989- 1997, 85 chorych z poziomem PSA ≥15 ng/ml (mediana 26 ng/ml, przedzia∏ 15-126
ng/ml) zosta∏o poddanych RP. Chorzy z palpacyjnie wyczuwalnym guzem stercza otrzymali 3 miesi´cznà neoadjuwantowà hor-
monoterapi´. U 36 chorych (42%) zastosowano wczesnà (w okresie 3-4 miesi´cy) adjuwantowà radioterapi´, ze wzgl´du na
stopieƒ zaawansowania pT3 i/lub stwierdzenie dodatnich marginesów chirurgicznych.
W y n i k i.  Mediana obserwacji wynios∏a 58 miesi´cy (2-104). Nawrót choroby wystàpi∏ u 33% chorych. 6 chorych (7%) zmar-
∏o w okresie obserwacji, 3 wskutek raka stercza z przerzutami. U chorych z guzami T1c obserwowano znaczàco ni˝szy odse-
tek nawrotów (p=0,03), ni˝ w grupie chorych z guzem wyczuwalnym w przedoperacyjnym badaniu per rectum (cT2 i cT3).
Wiek powy˝ej 65 lat okaza∏ si´ byç znaczàcym negatywnym czynnikiem prognostycznym w odniesieniu do odsetka nawrotów
biochemicznych (p=0,01). U chorych uzupe∏niajàco napromienianych obserwowano znaczàco ni˝szy odsetek nawrotów
biochemicznych w porównaniu do chorych, u których nie stosowano radioterapii (p=0,05). Wykazano, ˝e przedoperacyjny po-
ziom PSA nie mia∏ istotnego znaczenia prognostycznego w odniesieniu do cz´stoÊci nawrotów biochemicznych w analizowa-
nej grupie chorych. Jakkolwiek, chorzy z zaj´ciem p´cherzyków nasiennych (pT3c), u których znacznie cz´Êciej obserwowa-
no nawroty biochemiczne, mieli znaczàco wy˝szy poziom przedoperacyjnego PSA (p=0,05).
W n i o s k i.  U wybranych chorych z niewyczuwalnym palpacyjnie w badaniu per rectum rakiem stercza i przedoperacyjnym
poziomem PSA ≥15 ng/ml (mediana 26 ng/ml), radykalna prostatektomia mo˝e stanowiç opcj´ terapeutycznà. U m∏odych cho-
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Introduction
In spite of PSA screening, 15 % of the prostate cancer pa-
tients are diagnosed with a PSA >20 ng/ml [1-4]. Patients
with PSA >10 ng/ml, with non-palpable or localized pro-
state cancer are good candidates for either RP or RT [1].
Patients with higher (>20 ng/ml) PSA have a 60-80%
biochemical recurrence rate 5 years after either RP or
RT [5]. Stamey showed that patients with peripheral zone
cancers with PSA above 15 ng/ml have a low chance of
biochemical recurrence -free status [6, 7]. There is no
consensus in terms of what level of PSA should be consi-
dered a contraindication for RP.
Material and methods
From a database of 500 consecutive patients who underwent
RP between 1989 and 1997 at the University of Florida, eighty-
-five patients with serum prostate specific antigen (PSA) ≥15
ng/ml at diagnosis, (median 26 ng/ml, range 15-126 ng/ml) were
reviewed. The median age of these patients was 63 years (range
47-75 years). Median PSA of patients with PSA ≥15 ng/ml who
underwent RP between 1989-1992 was 31ng/ml (range 15-126)
compared to 20 ng/ml (range 15-90) in patients operated be-
tween 1993-1997. Patients with extreme values of PSA were
operated according to the patient's decision after appropriate in-
formed consent based on literature data available at that time.
Preoperative diagnosis was made by digital rectal examina-
tion (DRE); serum PSA and transrectal ultrasound (TRUS)
guided prostate biopsies.
Patients with palpable tumors received three months of
neoadjuvant hormone therapy with LH-RH analogs. After RP,
patients with positive surgical margins and extracapsular exten-
sion received adjuvant radiation therapy with 64 Gy administe-
red in 36 sessions using a four – field technique, three – four
months after RP.
Patients with positive lymph nodes (8 patients = 9.5 %) re-
ceived long term HT.
The same pathologist reviewed the postoperative speci-
men slides. (WM) After surgery, the patients were followed
with serum PSA every 4 months for the first two years and eve-
ry six moths after that. Criteria for treatment failure were: detec-
table serum PSA, biopsy proven and /or palpable local recurren-
ce or bone metastases on nuclear scan. At the time of biochemi-
cal failure, patients were started on hormone therapy
(continuous or intermittent), while patients who did not receive
adjuvant RT and suspected of having local failure received salva-
ge radiation therapy.
S t a t i s t i c a l  a n a l y s i s
The chi square test was used to assess the significance of the
difference between several subgroups of patients. The Univaria-
te log-rank test was utilized to assess the effect on progression of
the prognostic variables. The Cox proportional hazard estimate
and the Logistic regression analysis were used for the multivaria-
te statistical analysis of the prognostic variables found to be signi-
ficant by the univariate analysis. [8]
Results
85 consecutive patients were reviewed. The median follow
up was 58 months (range 2-104 mos.). Three patients
(3.5%) died of metastatic prostate cancer. The overall
progression rate was 33 % (28 patients). The median time
to progression was 27 months (range 4-75 mos.). Six pa-
tients (7%) had DRE detectable local and biochemical re-
currence, while 22 patients (26%) experienced only bio-
chemical recurrence. Table I summarizes the distribution
of the patients according to the prognostic variables and
relapse rates.
The recurrence rates according to different clinical
stages are illustrated in Table I and in Figure 1. Patients
with T1c cancers had significantly lower biochemical re-
currence rates compared to patients with palpable cancer
(p = 0.03) (7% vs. 33%). The biochemical recurrence
rates corresponding to the pathological stages are illu-
strated in Table I and Figure 2. Strikingly, the patients
in the pT2 group had higher relapse rate (51%) than the
patients with extra capsular extension (pT3a-b = 6%),
(p=0.02, Table I and Figure 2).
Table I. The distribution of patients according to PSA, 
clinical stage (cT), pathological stage (pT), 
specimen Gleason score (pGl) and median age. The values marked
with asterisk have statistical significance
Patient number Relapse (%) P
(%) value
PSA 15-20 36 (42%) 14 (39%)
21-40 25 (30%) 6 (24%)
>40 24 (28%) 8 (33%)
cT T1c 14 (16.4%) 1 (7%)* P=0.03
T2 48 (56.4%) 16 (33%)
T3 23 (27.2%) 11 (48%)
pT PT2 37 (43.5%) 19 (51%)* P=0.02
PT3a, b 16 (23.5%) 1 (6%)*
PT3c 20 (23.5%) 8 (40%)
PT4 4 (5%) 0%
N+ 8 (9.5%) 0%
pGl ≤6 27 (32%) 12 (45%)* P=0.01
7 21 (25%) 5 (23%)
≥8 37 (43%) 11 (30%)
Age ≤65 46 (54%) 11 (24%)* P=0.01
>65 39 (46%) 17 (43.5%)
The pT3c group (seminal vesicle invasion) had a re-
lapse rate of 40%. Within the pT3c-group, 16 patients
(75 %) received adjuvant radiation. Eight (50%) of these
rych z rakiem stercza, przedoperacyjny poziom PSA w surowicy nie powinien sam w sobie stanowiç przeciwwskazania do RP.
W przypadku stwierdzenia raka przekraczajàcego torebk´ stercza, autorzy polecajà wielodyscyplinarne post´powanie, z wyko-
rzystaniem radioterapii uzupe∏niajàcej.
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patients relapsed. The mean preoperative PSA of the
pT3c patients who recurred was significantly higher than
that of the patients who did not (44 ng/ml vs. 27 ng/ml,
p=0.05).
None of the patients with pT4 disease relapsed. Ho-
wever, the group is very small (four patients) and conse-
quently has no statistical power.
Overall, 23 (27%) patients had positive surgical mar-
gins (+SM). Positive surgical margins were not associated
with a higher biochemical relapse rate.
36 patients (42 %) were treated with adjuvant posto-
perative radiation. Overall, there was a statistically signi-
ficant difference in the biochemical recurrence rate in
the favor of patients who received adjuvant radiation
compared to those who did not (p=0.05, Figure 3). The
preoperative PSA was not statistically different in these
two groups (29 ng/ml versus 21 ng/ml).
Patients with age above 65 at the time of RP were fo-
und to have a statistically significant higher biochemical
relapse rate compared to younger patients. (p=0.01, Figu-
re 4).
There was a significantly higher relapse rate in pa-
tients with Gleason score 6 in comparison to the patients
with Gleason score ≥7. (p=0.01, Figure 5). Also, Gle-
ason score 6 was found more frequently in pT2 patients
(correlation coefficient, r = 0.25, p = 0.01). As stated
before, the pT2 stage group also had higher biochemi-
cal relapse rate than the rest of the patients.
The multivariate logistic regression and Cox pro-
portional hazard estimate analysis failed to identify any
particular individual prognostic factor within the factors
identified as statistically significant by the univariate ana-
lysis.
Figure 1. Biochemical relapse rates according to DRE (p=0.03) Figure 2. Biochemical relapse rate according to pT2 vs. pT3 (p=0.02)
Figure 3. Biochemical relapse rate according to post radical prostatec-
tomy (RP) radiation (RT) (p=0.05)




Serum PSA is an important prognostic variable in pa-
tients with prostate cancer [1]. The chances for biochemi-
cal relapse free status with PSA >15-20 ng/ml are remo-
te according to some authors, and consequently RP may
not be justified [4, 5].
On the other hand, Hanks et al. also concluded that
RT alone is not an optimal therapy for the patients with
high PSA. Only 28 % of his patients with PSA >20 were
biochemical relapse free at four years of followup. A mul-
timodality approach was therefore suggested as appro-
priate in these cases and the importance of local control
was emphasized [2].
Scardino et al. reported an actuarial 5 year biochemi-
cal recurrence free rate of 50 % after RP in patients with
preoperative PSA = 20-100 and clinically localized dise-
ase [10].
In the present study, the overall biochemical relapse
rate was 33 %, significantly lower than in the Scardino et
al. data [10].
Patients with nonpalpable prostate cancer had a bio-
chemical recurrence rate significantly lower (7%) compa-
red to patients with palpable cancers (cT2 – 33% and
cT3 – 48%, p=0.03). The distribution of PSA was not si-
gnificantly different within the different clinical stages.
The majority (60%) of T1c patients had pathological
extracapsular disease and consequently received adju-
vant radiation. The biochemical relapse rate of the pa-
tients with nonpalpable prostate cancer was significantly
lower than in other reported series [10].
The relapse rate for the pT3a, b cases in the pre-
sent study was only 6 %, comparable to the data publi-
shed by Valicenti et al. on patients with pT3 stage but
with lower preoperative PSA [11]. Seventy percent (70%)
of the pT3a, b patients, (11/16) received adjuvant radia-
tion with 64Gy, a fact that may explain this low relapse ra-
te [12].
The relapse rate of patients with seminal vesicle inva-
sion (pT3c) was 40%, comparable to other published re-
sults [13].
The relapse rate in the pT2 group in our study was
51% (19/37 patients), surprisingly higher than in the pT3
group. It is conceivable that the use of neoadjuvant HT in
92 % (34/37 patients) of the pT2 patient group resulted in
a pathological „down staging” [14]. Consequently, none of
the pT2 patients received any RT [15].
Conclusions
This is a retrospective study and consequently it suffers
the drawbacks of such a report. It also contains data on
patients with preoperative PSA that nowadays would re-
frain many urologists from any curative therapeutic at-
tempt. In spite of these facts, we were able to point out
some significant conclusions.
Overall, preoperative PSA (median 26 ng/ml) had
no prognostic significance in the present study, however,
in patients with seminal vesicle invasion preoperative
PSA correlated significantly with the biochemical relapse
rate.
Patients with extra capsular tumor extension treated
with adjuvant postoperative radiation had a relapse rate
comparable to that of patients with organ – confined dise-
ase in other reported series.
Neoadjuvant HT may hamper the optimal pathologi-
cal staging and consequently it may deprive some pa-
tients of adjuvant RT if such an approach is contemplated.
Patients under the age of 65, with cT1c prostate can-
cer did significantly better in terms of biochemical relap-
se, when compared to the rest of the patients. RP may be
a feasible therapeutic option in these patients. We enco-
urage the selective use of a multimodality treatment ap-
proach, incorporating adjuvant radiation after RP.
We also suggest that in young patients the level of se-
rum PSA should be used selectively as a contraindica-
tion for RP.
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